Details for Patent: 10,265,308

« Back to Dashboard

Which drugs does patent 10,265,308 protect, and when does it expire?

Patent 10,265,308 protects RELEXXII and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 10,265,308

Title:	Dose-dumping resistant controlled release dosage form
Abstract:	The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
Inventor(s):	Hernan D. Benedetti, Cristian R. FRANCO, Guido S. BIGATTI, Joaquina Faour, Ana C. PASTINI
Assignee:	Acella Pharmaceuticals LLC
Application Number:	US15/656,237
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,265,308

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-001	Jun 23, 2022		RX	Yes	No	10,265,308		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-002	Jun 23, 2022		RX	Yes	No	10,265,308		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-003	Jun 23, 2022		RX	Yes	No	10,265,308		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-004	Jun 23, 2022		RX	Yes	No	10,265,308		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-005	Jun 23, 2022		RX	Yes	No	10,265,308		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

International Family Members for US Patent 10,265,308

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109157
Canada	2992767
Chile	2017001919
Uruguay	37344